Processing Your Payment
Please do not leave this page until complete. This can take a few moments.
Your search found 63 results
-
May 22, 2017 -Biostage will be delisted from the NASDAQ stock market if it loses an upcoming appeal, after the company failed to raise its bid price to $1 within a given 180-day period.
May 22, 2017 -Biostage will be delisted from the NASDAQ stock market if it loses an upcoming appeal, after the company failed to raise its bid price to $1 within a given 180-day period.
May 15, 2017 -The Worcester Railers Hockey Club, Reliant Medical Group, Clinton Financial Services, and others all either hired or promoted employees.
May 15, 2017 -The Worcester Railers Hockey Club, Reliant Medical Group, Clinton Financial Services, and others all either hired or promoted employees.
May 11, 2017 -Biostage, which develops bioengineered organ implants, reported it lost $3.8 million in the first quarter, leaving it with only enough cash through the end of the year.
May 11, 2017 -Biostage, which develops bioengineered organ implants, reported it lost $3.8 million in the first quarter, leaving it with only enough cash through the end of the year.
- May 10, 2017 -
Stephen F. Badylak was appointed as co-chair of the Scientific Advisory Board at Biostage in Holliston. He is a professor in the department of surgery, and deputy director of the…
May 10, 2017 -Stephen F. Badylak was appointed as co-chair of the Scientific Advisory Board at Biostage in Holliston. He is a professor in the department of surgery, and deputy director of the…
February 10, 2017 -Holliston organ implant company Biostage is offering roughly $8 million in stock, three months after it was threatened to be removed from the NASDAQ stock exchange.
February 10, 2017 -Holliston organ implant company Biostage is offering roughly $8 million in stock, three months after it was threatened to be removed from the NASDAQ stock exchange.
December 1, 2016 -Bioengineered organ transplant company Biostage's stock lept more than 25 percent after the company announced it received a designation that will save the company time and money as it pushes its…
December 1, 2016 -Bioengineered organ transplant company Biostage's stock lept more than 25 percent after the company announced it received a designation that will save the company time and money as it pushes its…
November 22, 2016 -Holliston's Biostage organ implant company has been given 180 days to raise its stock price above $1 or risk delisting from the NASDAQ stock market.
November 22, 2016 -Holliston's Biostage organ implant company has been given 180 days to raise its stock price above $1 or risk delisting from the NASDAQ stock market.
November 10, 2016 -Holliston's Biostage will need to raise more money to get to human trials of its bioengineered organ implants to treat throat cancers as its third quarter losses exceed $3 million with a little over…
November 10, 2016 -Holliston's Biostage will need to raise more money to get to human trials of its bioengineered organ implants to treat throat cancers as its third quarter losses exceed $3 million with a little over…
October 7, 2016 -Under the advisement of the U.S. Food & Drug Administration, Biostage has decided to extend their animal testing of its Cellframe organ implants and push back its investigational new drug (IND)…
October 7, 2016 -Under the advisement of the U.S. Food & Drug Administration, Biostage has decided to extend their animal testing of its Cellframe organ implants and push back its investigational new drug (IND)…
August 11, 2016 -Holliston's Biostage has cut its losses down even as it prepares to launch human trials of its Cellframe organ implants.
August 11, 2016 -Holliston's Biostage has cut its losses down even as it prepares to launch human trials of its Cellframe organ implants.
August 1, 2016 -Over the past year, Holliston-based Biostage has revamped its upper management, changed its name and used its technology to partially recreate the esophaguses of several Yucatan pigs.
August 1, 2016 -Over the past year, Holliston-based Biostage has revamped its upper management, changed its name and used its technology to partially recreate the esophaguses of several Yucatan pigs.
July 21, 2016 -Holliston biotechnology firm Biostage has named Harout DerSimonian to the newly created position of chief science officer as the company closes in on human trials of its Cellspan esophageal implants.
July 21, 2016 -Holliston biotechnology firm Biostage has named Harout DerSimonian to the newly created position of chief science officer as the company closes in on human trials of its Cellspan esophageal implants.
June 29, 2016 -Holliston biotechnology firm Biostage has filed for a designation that would allow it to fast-track registrations for its Cellspan esophageal implants and gain a full exemption from the FDA's…
June 29, 2016 -Holliston biotechnology firm Biostage has filed for a designation that would allow it to fast-track registrations for its Cellspan esophageal implants and gain a full exemption from the FDA's…
June 22, 2016 -Biostage is moving closer to human trials of its esophagus regeneration technology, anticipated to take place in 2017, on the back of an additional $5 million in funding gained through a stock offer.
June 22, 2016 -Biostage is moving closer to human trials of its esophagus regeneration technology, anticipated to take place in 2017, on the back of an additional $5 million in funding gained through a stock offer.
May 16, 2016 -The bioengineered organ implant company Biostage has announced it will release 2.8 million shares of common stock in an effort to raise $5 million.
May 16, 2016 -The bioengineered organ implant company Biostage has announced it will release 2.8 million shares of common stock in an effort to raise $5 million.
